Coffee is a popular beverage worldwide with various nutritional benefits. Diterpene cafestol, one of the major components of coffee, contributes to its beneficial effects through various biological activities such as chemopreventive, antitumorigenic, hepatoprotective, antioxidative and antiinflammatory effects. In this study, we examined the precise molecular mechanism of the antiinflammatory activity of cafestol in terms of prostaglandin E 2 (PGE 2 ) production, a critical factor involved in inflammatory responses. Cafestol inhibited both PGE 2 production and the mRNA expression of cyclooxygenase (COX)-2 from lipopolysaccharide (LPS)-treated RAW264.7 cells. Interestingly, this compound strongly decreased the translocation of c-Jun into the nucleus and AP-1 mediated luciferase activity. In kinase assays using purified extracellular signal-regulated kinase 2 (ERK2) or immunoprecipitated ERK prepared from LPS-treated cells in the presence or absence of cafestol, it was found that this compound can act as an inhibitor of ERK2 but not of ERK1 and mitogen-activated protein kinase kinase 1 (MEK 1). Therefore our data suggest that cafestol may be a novel ERK inhibitor with AP-1-targeted inhibitory activity against PGE 2 production in LPS-activated RAW264.7 cells.
Cyclooxygenase (COX)-2 is an inflammatory gene catalyzing prostaglandin E 2 (PGE 2 ) production from a substrate lipid, arachidonic acid. 1) Inflammatory signals greatly enhance the expression level of COX-2, particularly in inflammatory cells such as monocytes, macrophages, endothelial cells, and fibroblasts.
2) Numerous trials to develop a promising antiinflammatory drug therefore are still targeted at suppressing PGE 2 production as well as COX-2 expression.
3) A better understanding of the induction mechanism of COX-2 expression and PGE 2 production would allow us to consider various levels of inflammatory signaling pathways as target molecules. The biochemical pathways include the levels of transcription factors (nuclear factor (NF)-kB and AP-1) and upstream signaling cascades such as mitogen-activated protein kinase (MAPK) containing extracellular signal-regulated kinase (ERK), p38, and C-Jun N-terminal kinase (JNK), phosphoinositide-3-kinase (PI3K)/Akt, and inhibitor of kB (IkB) kinase (IKK)/IkBa. 4, 5) Coffee is a popular beverage worldwide and has been studied for a long time due to its controversial pharmacology thought to be either beneficial or adverse. Although coffee has been reported to increase blood cholesterol level and blood pressure, and cause hypersecretion of gastric juice, it is increasingly noted that coffee also has somewhat beneficial effects such as antiinflammatory and anticarcinogenic properties. [6] [7] [8] The major compounds to explain these pharmacologically beneficial effects are diterpenes such as cafestol ( Fig. 1 ) and kahweol. 6) In spite of numerous papers on the anticancer activities of coffee and its ingredients, so far, few studies demonstrated the effect of cafestol on inflammatory mediator production in macrophages. The Jeong group in Korea found that cafestol has strong inhibitory activity on PGE 2 production by suppressing the NF-kB activation pathway. 9) They found that the lipopolysaccharide (LPS)-induced activation of NF-kB is down-regulated by cafestol by preventing IkBa degradation and inhibiting IkB kinase (IkK) activity. 9) Although that study contributed to understanding the immunopharmacologic roles of cafestol, there is a possibility that other inflammatory signaling pathways can serve as target sites for cafestol action. To expand our knowledge of the beneficial roles of coffee, we consumed to evaluate the antiinflammatory mechanism of cafestol in terms of other major inflammatory signaling pathways such as MAPK (ERK, p38, and JNK) and their relevant transcription factor AP-1.
MATERIALS AND METHODS
Materials Cafestol (Fig. 1 , purity: 99%), phorbol-12-myristate-13-acetate (PMA), and lipopolysaccharide (LPS, Escherichia coli 0111:B4) were purchased from Sigma (St. Louis, MO, U.S.A.). LY294002, wortmannin, U0126, SP600125, and SB203580 were obtained from Calbiochem (La Jolla, CA, U.S.A.). Fetal bovine serum (FBS) was obtained from GIBCO (Grand Island, NY, U.S.A.). The ERK kinase assay kit was purchased from Millipore (Billerica, MA, U.S.A.). All other chemicals were of reagent grade. Total or phospho-specific antibodies to c-Jun, c-fos, JNK, p38, ERK, b-tublin, and lamin A/C were purchased from Cell Signaling (Beverly, MA, U.S.A.).
Cell Culture RAW264.7 and HEK293 cells (American Type Culture Collection, Rockville, MD, U.S.A.) were maintained in complete RPMI-1640 medium (supplemented with 100 U/ml of penicillin, 100 mg/ml of streptomycin, and 10% fetal bovine serum).
PGE 2 Production
The modulatory effect of cafestol on PGE 2 release was determined as previously described. 10) RAW264.7 cells (2ϫ10 6 cells/ml) were incubated with LPS and various concentrations of cafestol for 24 h. Supernatants were collected and assayed for PGE 2 content using the PGE 2 enzyme immunoassay kit (Amersham, Little Chalfont, Buckinghamshire, U.K.).
MTT Assay (Colorimetric Assay) for Measurement of Cell Proliferation Cell proliferation and the cytotoxicity of cafestol were determined using the conventional 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as previously reported.
10)
Determination of LPS-Inducible COX-2 Gene Expression For the evaluation of COX-2 mRNA expression levels, the total RNA from the LPS treated-RAW264.7 cells (5ϫ10 6 cells/ml) was prepared by adding TRIzol Reagent (Gibco BRL) according to the manufacturer's protocol, as reported previously.
11) The primers (Bioneer, Seoul, Korea) used in this experiment were: COX-2 (F-5Ј-CACTACATCCTGAC-CCACTT-3Ј and R-5Ј-ATGCTCCTGCTTGAGTATGT-3Ј); and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (F-5Ј-CACTCACGGCAAATTCAACGGCAC-3Ј and 5Ј-GACTCCACGACATACTCAGCAC-3Ј).
Luciferase Reporter Gene Activity Assay Since RAW264.7 cells are not easy to transfect with interesting DNA constructs, HEK293 cells (1ϫ10 6 cells/ml) were transfected with 1 mg of plasmids with AP-1-Luc as well as bgalactosidase using the calcium phosphate method in a 12-well plate. The cells were used for experiments 48 h after transfection. Luciferase assays were performed using the Luciferase Assay System (Promega, Madison, WI, U.S.A.).
12)
Immunoblotting For total protein extraction: RAW 264.7 cells were harvested, washed with cold phosphate buffered saline (PBS), and lysed in lysis buffer (Tris-HCl 20 mM, pH 7.4, EDTA 2 mM, EGTA 2 mM, b-glycerophosphate 50 mM, sodium orthovanadate 1 mM, dithiothreitol 1 mM, 1% Triton X-100, 10% glycerol, leupeptin 10 mg/ml, aprotinin 10 mg/ml, pepstatin 10 mg/ml, benzimidine 1 mM and phenylmethane sulphonylfluoride 2 mM) for 30 min with rotating at 4°C. Lysates were clarified by centrifugation at 16000ϫg for 10 min at 4°C. For nuclear protein extraction, nuclear proteins were obtained through three steps. After the treatment, cells were harvested and lysed in 500 ml of lysis buffer (KCl 50 mM, 0.5% Nonidet P-40, HEPES 25 mM, phenylmethylsulfonyl fluoride 1 mM, leupeptin 10 mg/ml, aprotinin 20 mg/ml, and 100 mM 1,4-dithiothreitol) on ice for 4 min. Cells lysates were centrifuged at 14000 rpm for 1 min at 4°C. In the second step, the pellet was washed with the washing buffer, which was the same as the lysis buffer excluding Nonidet P-40. In the final step, the nuclei were incubated with an extraction buffer (KCl 500 mM, 10% glycerol, HEPES 10 mM, NaCl 300 mM, 1,4-dithiothreitol 0.1 mM, PMSF 0.1 mM, leupeptin 2 mg/ml, and aprotinin 2 mg/ml) and centrifuged at 14000 rpm for 5 min. The supernatant was collected as the nuclear protein extract. Soluble cell lysates were immunoblotted, and phospho-ERK levels were visualized as previously reported.
11)
ERK Kinase Assay For evaluating ERK kinase inhibitory activity with purified enzyme, a kinase profiler service from Millipore was used. In a final reaction volume of 25 ml, ERK1 (human), ERK2 (human), or MAPK kinase (MEK) 1 (human) (1-5 mU) was incubated with the reaction buffer. The reaction was initiated by the addition of MgATP. After incubation for 40 min at room temperature, the reaction was stopped by the addition of 5 ml of a 3% phosphoric acid solution. Ten microliters of the reaction product were then spotted onto a P30 filtermat and washed three times for 5 min in phosphoric acid 75 mM and once in methanol prior to drying and scintillation counting. To determine the inhibitory effects of cafestol on LPS-activated ERK activity, immunoprecipitated ERK prepared from LPStreated RAW264.7 cells (5ϫ10 6 cells/ml) in the presence or absence of cafestol were incubated with myelin basic protein (MBP), according to the manufacturer's instructions. The ERK kinase activity was determined with anti-phospho-MBP antibody after immunoblotting analysis.
Statistical Analysis Student's t-test and one-way ANOVA were used to determine the statistical significance of differences between values for the various experimental and control groups. Data expressed as meanϮS.E.M. were taken from at least three independent experiments performed in triplicate (Figs. 2A, B and 3A, D, E) . The data (Figs. 2C and 3B, C) are representative of three different experiments with similar results. p values of 0.05 or less were considered to represent statistically significant differences.
RESULTS AND DISCUSSION
In this study, we found a novel inhibitory pathway by which cafestol effectively blocks the AP-1 pathway in LPSstimulated macrophages. Cafestol clearly suppressed PGE 2 production ( Fig. 2A) in macrophages after LPS stimulation in a dose-dependent manner (IC 50 valueϭ45.7 mM), as did standard compounds (LY294002 and wortmannin) ( Fig. 2A , right panel). Since there was no effect on normal cell viability by cafestol after 12-and 24-h incubation (Fig. 2B) , cafestol-derived inhibition does not appear to be due to its nonspecific action. However, the inhibitory potency was different from that in a previous report in which the IC 50 value of cafestol was around 5 mM.
9) Continuous evaluation also indicated that cafestol-mediated inhibition of PGE 2 production may occur at the transcriptional level, because cafestol decreased the mRNA synthesis of COX-2 observed under the same conditions (Fig. 2C) . This inhibitory pattern is generally seen in numerous PGE 2 inhibitory compounds with transcriptional regulatory features, 13, 14) and accordingly the identification of the transcription factor(s) and upstream signaling events were continuously observed.
The transcriptional control of PGE 2 production in macrophages is mediated by redox-sensitive transcription factors such as NF-kB and AP-1. Because cafestol has been reported to suppress NF-kB activation, 9) we mainly focused on understanding the involvement of AP-1. To do this, the translocational levels of AP-1 (c-Jun and c-fos) in the nuclear fraction from LPS-treated RAW264.7 cells was first examined using immunoblotting analysis. As Fig. 3A depicts, the levels of translocated c-Jun and phospho-c-Jun in the nuclear fraction were interrupted by cafestol 25 and 100 mM, without any contamination of cytosolic proteins, as confirmed with cytosolic b-tublin. 15) In contrast, c-Jun and c-fos were not found in the normal nuclear fraction, indicating inducible activation of AP-1 (c-Jun/c-fos) during LPS treatment. In agreement with those results, PMA-upregulated luciferase activity in HEK293 cells transfected with a luciferase reporter construct containing binding sites for AP-1 11) was also dose dependently suppressed by cafestol treatment (Fig. 3C) , suggesting that the molecular target of cafestol appears in a downstream pathway, activated commonly during both LPS and PMA treatment for AP-1 activation.
Since the translocation of AP-1 is mediated by the phosphorylation of MAPK, 16) we next investigated the potential involvement of MAPK in cafestol inhibition. Interestingly, however, the phosphorylation of MAPK (ERK, JNK, and p38) was not blocked by various concentrations of cafestol (Fig. 3B) . The negative effects of cafestol on MAPK activation was also observed even when incubated for various times (data not shown), implying that the MAPK pathway is not a target of the pharmacology of cafestol. Nonetheless, among MAPK inhibitors, U0126, an inhibitor of ERK kinase (MEK) strongly suppressed the nuclear translocation of AP-1 (c-Jun and c-fos) by LPS in RAW264.7 cells and luciferase activity mediated by AP-1 activation in HEK293 cells cultured with PMA (Fig. 3D) , suggesting that the ERK (but not the p38 and JNK) activation pathway could play a central role in this AP-1 up-regulation event (Fig. 3D) . Based on these results, it was assumed that cafestol may not only block the ERK pathway but also suppress a biochemical step between c-Jun translocation and the phosphorylation of ERK. Because the immunoblotting results shown in Fig. 3B indicated that cafestol did not block each activational phosphorylation step of ERK, p38, and JNK, and the inhibitors to p38 and JNK did not suppress or only weakly suppressed AP-1 (c-Jun/c-fos) translocation as well as AP-1-mediated luciferase activity (Fig. 3D) , the only method to determine cafestol activity was to explore ERK kinase itself. Therefore, the enzyme kinase assay was carried out to ascertain testing whether this compound was able to suppress the kinase activity of ERK (ERK 1/2) and its upstream kinase, MEK1, directly. 17) Interestingly, cafestol only decreased the enzymatic activity of ERK2, but not that of ERK1 and MEK1, at 100 mM (Fig. 3E) . These data therefore imply that cafestol could block PGE 2 production, COX-2 expression, and cJun/AP-1 translocation by directly blocking ERK2. Moreover, the lack of inhibition of MEK1 by cafestol strongly indicates that ERK2 inhibition by cafestol is not due to a simple treatment effect. In agreement with the result of the purified enzyme assay, cafestol also significantly suppressed immunoprecipitated ERK activity, assessed by measuring the phosphorylation level of its substrate protein MBP, performed with LPS-treated cells in the presence or absence of cafestol (Fig. 3F ). Therefore these data suggest that cafestol could act as an inhibitor of ERK (2) .
It is widely reported that the ERK activation pathway is involved in the pathophysiologic onset of various diseases such as cancer, stroke, diabetes, cardiovascular disease, au- toimmune diseases, atherosclerosis, allergic reactions, inflammation, and neurologic disorders. [18] [19] [20] Due to this, numerous researchers are now developing potent ERK pathway inhibitors. U0126 and PD98059 are known for MEK-inhibitory activity. On the other hand, 3-(2-aminoethyl)-5-((4-ethoxyphenyl)methylene)-2,4-thiazolidinedione has been reported to inhibit ERK activity (IC 50 ϭ25 mM) by suppressing ERK binding to its protein substrates, but not to the ATP domain in HeLa, A549, and SUM-159 tumor cells. 21, 22) In addition, pyrazolylpyrrole-type CAY10561 is a potent, ATP-competitive inhibitor of ERK2 (K i ϭ2 nM) with higher selectivity for ERK2. 23) Whether cafestol binds to ATP-binding sites or other substrate-binding areas and which functional groups of cafestol are important for ERK2 inhibition have not yet been elucidated. Therefore detailed characterization of inhibitory mechanism of action and modification of chemical structures to optimize the inhibitory potency should be undertaken.
In conclusion, we found that cafestol inhibits PGE 2 production from LPS-treated RAW264.7 cells at the transcriptional level. In particular, this compound downregulates the translocation of c-Jun and AP-1-mediated luciferase activity. The direct kinase assay showed that cafestol can act as an inhibitor of ERK2 but not of ERK1 and MEK1. Therefore our data suggest that cafestol could be a novel ERK inhibitor with AP-1-targeted inhibitory activity against PGE 2 production in LPS-activated RAW264.7 cells. 
